ORIGINAL ARTICLE

Assessing the extent of non-aggressive cancer in clinically detected stage I non-small cell lung cancer

Minal S Kale,¹ Keith Sigel,¹ Grace Mhango,¹ Juan P Wisnivesky^{1,2}

¹Division of General Internal Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York City, New York, USA
²Division of Pulmonary, Critical Care, and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York City, New York, USA

Correspondence to

Dr Minal S Kale, Division of General Internal Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA;
 minal.kale@mountsinai.org

Received 23 March 2017
 Revised 29 August 2017
 Accepted 25 September 2017
 Published Online First
 20 October 2017

ABSTRACT

Background Overdiagnosis among clinically detected lung cancers likely consists of cases that are non-aggressive and slowly progressive and will never disseminate, cause symptoms or be a threat to a subject's survival, even if untreated. In this study, we estimate the prevalence of non-aggressive lung cancers from a large, population-based cancer registry.

Methods We identified individuals ≥ 65 years with histologically confirmed, untreated stage I non-small cell lung cancers (NSCLCs) from the Surveillance, Epidemiology, and End Results-Medicare registry. We estimated the rate of non-aggressive lung cancers by determining the point at which the cumulative lung cancer-specific survival curve no longer changed (ie, the slope approaches zero). At this point, there are no additional deaths due to progressive lung cancer observed among untreated patients after adjusting for deaths from competing risks (these long-term survivors can be considered 'non-aggressive cases').

Results The overall rate of non-aggressive cancers among 2197 clinically detected cases of untreated stage I NSCLC was 2.4%, 95% CI: 1.0% to 3.8%. The rate of non-aggressive cancer was 1.9% (95% CI: 0.0% to 4.9%) for women and 2.4% (95% CI: 0.7% to 4.1%) for men ($p=0.84$). When stratifying by tumour size, non-aggressive cancer rates were 10.2% (95% CI: 0.0% to 29.3%), 2.1% (95% CI: 0.0% to 9.2%), 4.9% (95% CI: 0.0% to 10.3%), 1.8% (95% CI: 0.0% to 5.2%) and 0.0% (95% CI: 0.0% to 1.0%) for tumour sizes <15 mm, 15–24 mm, 25–34 mm, 35–44 mm and ≥ 45 mm, respectively. In comparison with the smallest tumour sizes (<15 mm), the rates of non-aggressive cancers were not statistically significantly different for tumour sizes 15–24 mm ($p=0.36$), 25–34 mm ($p=0.57$), 35–44 mm ($p=0.38$) and tumour sizes >45 mm ($p=0.30$).

Discussion We found relatively low rates of non-aggressive cancers among clinically detected, stage I NSCLC regardless of sex or size. Our findings suggest that most clinically diagnosed early stage cancers should be treated with curative intent.

INTRODUCTION

In the context of medical screening, an 'overdiagnosed' cancer refers to a cancer which would never have been diagnosed in the patient's lifetime if screening had not taken place.^{1–3} However, a similar phenomenon also occurs among clinically detected cancers and consists of cancers that are non-aggressive and slowly progressive and will never disseminate, cause symptoms or be a threat to a subject's survival, even if untreated. It is likely

Key messages

What is the key question?

- What are the rates of non-aggressive cancers in stage I non-small cell lung cancer?

What is the bottom line?

- In a population-based cancer registry, there were low rates of non-aggressive cancers.

Why read on?

- We used a sound statistical method (competing risks) to assess rates of non-aggressive cancers and also conducted analyses stratified by age, gender, the presence of COPD, tumour size and histology.

that these cancers have been found incidentally via imaging for another purpose. The presence of clinically diagnosed, non-aggressive cancers may be influenced by certain patient characteristics, such as age and sex, as well as tumour characteristics, such as histology and tumour size, among other factors. Unfortunately, clinically diagnosed, non-aggressive cancer is difficult to ascertain at the time of diagnosis as there are no existing markers to differentiate aggressive versus non-progressive cancers. Treating these cancers potentially leads to unnecessary morbidity and mortality without a survival benefit.

The magnitude of non-aggressive cancers among non-screened lung cancers has previously been evaluated in observational cohorts. However, previous studies have been hindered by a failure to appropriately treat non-lung cancer deaths as a competing risk, leading to biased estimation of the extent of this issue. In the context of lung cancer screening, older studies evaluating the role of chest radiograph screening suggested that overdiagnosis may explain some of the excess cancers and stage shift observed among screened smokers.^{4,5} More recent modelling studies have estimated that approximately 1.5–6.6% of all cancers (including screen-detected cancers) are overdiagnosed.⁶ Analysis of data from the National Lung Screening Trial (NLST) has yielded estimates of overdiagnosis with a conservative estimate of 18.5% and a wide range of plausible values depending on the histological subtype and applied definition.⁷ Data from European lung cancer screening trials have also suggested that lung cancer screening leads to overdiagnosis.^{8,9}

Understanding the true rate of non-aggressive cancers among clinically diagnosed lung cancers is

► <http://dx.doi.org/10.1136/thoraxjnl-2017-211149>

Check for updates

To cite: Kale MS, Sigel K, Mhango G, et al. *Thorax* 2018;**73**:459–463.

critical for evaluating their management. In this study, we used competing risks methods to assess lung cancer-specific survival of untreated patients with stage I non-small cell lung cancer (NSCLC) to estimate the extent of non-aggressive cancer from a large, population-based cancer registry.

METHODS

We identified individuals from the Surveillance, Epidemiology, and End Results (SEER) registry linked to Medicare claims.¹⁰ SEER is a coordinated, national cancer registry that collects detailed cancer information covering approximately 28% of the US population and is nationally representative.¹¹ Our sample consisted of patients ≥ 65 years diagnosed with histologically confirmed, untreated stage I NSCLC diagnosed between 1992 and 2010. In order to ensure complete ascertainment of lung cancer treatments, we further limited our cohort to Medicare beneficiaries with both Part A (inpatient) and Part B (outpatient) coverage and excluded patients in health maintenance organisations as they lacked complete and detailed claim information. To reduce the likelihood that patients had undetected mediastinal lymph node involvement, we only included individuals with a claim for a diagnostic CT of the chest, positron emission tomography (PET)-CT or mediastinoscopy in the 30 days preceding and 90 days beyond the date of diagnosis.

Sociodemographic information (age, sex, race, ethnicity, marital status and estimated income) was obtained from the SEER and Medicare databases. To evaluate the presence of COPD status of individuals at the time of cancer diagnosis, we used a combination of inpatient, outpatient and physician claims.^{12 13}

SEER cancer coding provided information enabling ascertainment of tumour histology (adenocarcinoma, squamous cell carcinoma, large cell carcinoma or other). Additionally, cancer stage was assessed using detailed SEER information on tumour location, size, local extension and lymph node involvement. Tumour sizes were classified into the following five categories: <15 mm, 15–24 mm, 25–34 mm, 35–44 mm and ≥ 45 mm. We defined stage I NSCLC based on the seventh edition of the American Joint Committee on Cancer system.¹⁴

We used Medicare claims to determine the diagnostic and staging workup of patients, including the use of CT, PET and mediastinoscopy. We evaluated the use of surgery, radiotherapy or chemotherapy using a combination of SEER and Medicare claims. Patients without evidence of claims or SEER data indicating the use of any of these strategies were classified as untreated and included in the cohort. SEER does not include robust information regarding the reason for lack of treatment of these individuals.

The primary study outcome, lung cancer-specific survival, was determined from SEER data, which have high levels of ascertainment.¹⁵ Cause of death (lung cancer vs non-lung cancer) was collected from SEER and was based on death certificate data. Survival time was determined as the interval from the date of diagnosis to the date of lung cancer death recorded by SEER. Subjects surviving past 140 months (to avoid estimating survival curves based on a small number of cases) or 31 December 2010 were censored.

STATISTICAL ANALYSIS

We evaluated the baseline characteristics of our study cohort using descriptive statistics. We estimated the rate of non-aggressive cancer by applying the definition proposed by Buell, wherein the point at which cumulative lung cancer-specific survival curve

no longer changes (ie, the slope approaches zero) can provide an estimate of cancer fatality among untreated cases.¹⁶ At this point, there are no additional lung cancer deaths (ie, progressive cancers) observed among a cohort of untreated patients with lung cancer, even after statistically adjusting for all deaths from other causes. Thus, surviving untreated lung cancer can be considered a 'non-aggressive' case. We determined the time point for estimating the rate of non-aggressive cancer based on the fatality curve for the entire cohort. Using these data, we selected the time point that corresponded to the derivative of the curve approaching zero. We generated survival curves by employing competing risks methods (conditional probability function (CPF)) to estimate the long-term lung cancer-specific survival. CPF methods estimate the risk of lung cancer fatality conditional on an absence of death from competing causes.¹⁷ Competing risk estimation is preferable to the Kaplan-Meier method as the latter leads to biased disease-specific survival estimates when there is substantial comorbidity. This is especially important in the case of lung cancer, which in most cases is due to tobacco and occurs in the elderly, with a subsequent higher risk of cardiovascular and pulmonary comorbidity. Moreover, untreated patients are a group with a substantial burden of comorbidities.

To determine whether non-aggressive cancer varies according to baseline characteristics, we used stratified analyses according to sex, age, histology, tumour size and the presence of COPD. We tested for differences in survival according to patient characteristics using a z-test based on the asymptotically normal distribution of the conditional probability.¹⁸ All analyses were performed using SAS statistical software (SAS Institute, Cary, North Carolina, USA). This study was determined to be exempt from the Icahn School of Medicine at Mount Sinai institutional review board prior to study commencement.

RESULTS

We identified 2725 individuals in the SEER-Medicare files with untreated, clinically detected, stage I NSCLC, of which 528 did not have a claim for a chest CT, PET or mediastinoscopy, resulting in a final sample of 2197 patients. Approximately 33% of the sample was between the ages of 65 and 74, 50% were between the ages of 75 and 84 and 17% were >85 years of age (table 1). The sample consisted of 51% women, 80% Whites, 12% Blacks, 3% Hispanic and 5% Other; 39% were married. Approximately 30%, 26%, 24% and 19% belonged to the first (lowest), second, third and fourth (highest) income quartiles. In terms of size distribution, 4%, 17%, 22%, 14% and 17% had tumour sizes of <15 mm, 15–24 mm, 25–34 mm, 35–44 mm and ≥ 45 mm, respectively. We did not have tumour size data for 26% of individuals due to lack of data in SEER. Tumours' histology was 41% adenocarcinoma, 40% squamous cell, 6% large cell and 13% other. Approximately 47% of the cohort had COPD.

The CPF curve showing the risk of lung cancer fatality conditional on no death from competing causes in the total population is shown in figure 1. The derivative of the conditional probability of lung cancer death approached zero at 100 months; this time point was used to assess non-aggressive cancer rates for all strata. The overall rate of non-aggressive cancer was 2.4%, 95% (CI): 1.0% to 3.8%. Figures 2–6 demonstrate the CPF curves stratified by gender, tumour size, histology, the presence of COPD and age, respectively. The estimated rate of non-aggressive cancer was 1.9% (95% CI: 0.0% to 4.9%) for women and 2.4% (95% CI: 0.7% to 4.1%) for men ($p=0.84$). When stratifying by tumour size, the estimated rate of non-aggressive

Table 1 Baseline characteristics of patients with clinically detected, stage I untreated non-small cell lung cancer

Characteristic, N (%)	Study population n=2197	95% CI
Age (years)		
65–74	725 (33)	31 to 35
75–84	1091 (50)	48 to 52
>85	381 (17)	16 to 19
Female	1118 (51)	49 to 53
Married	864 (39)	37 to 41
Race/ethnicity		
White	1767 (80)	79 to 82
Black	254 (12)	10 to 13
Hispanic	74 (3)	3 to 4
Other	102 (5)	4 to 6
Median income		
First quartile*	666 (30)	28 to 32
Second quartile	575 (26)	24 to 28
Third quartile	528 (24)	22 to 26
Fourth quartile	428 (19)	18 to 21
Diagnostic workup		
CT chest	2140 (97)	(97 to 98)
Positron emission tomography (PET)	306 (14)	(13 to 15)
Mediastinoscopy	34 (2)	(1 to 2)
COPD	1042 (47)	45 to 50
Year of diagnosis		
1992–1999	980 (45)	43 to 47
2000–2009	1217 (55)	53 to 57
Histology		
Adenocarcinoma	903 (41)	39 to 43
Squamous cell	875 (40)	38 to 42
Large cell	129 (6)	5 to 7
Other	290 (13)	12 to 15
Tumour size (mm) [†]		
<15	80 (4)	3 to 6
15–24	369 (17)	15 to 18
25–34	486 (22)	20 to 24
35–44	313 (14)	13 to 16
>45	377 (17)	16 to 19

*Lowest income quartile

[†]Five hundred and seventy-two (26%) with unknown tumour size.

cancer was 10.2% (95% CI: 0.0% to 29.3%), 2.1% (95% CI: 0.0% to 9.2%), 4.9% (95% CI: 0.0% to 10.3%), 1.8% (95% CI: 0.0% to 5.2%) and 0.0% (95% CI: 0.0% to 1.0%) for tumour sizes <15 mm, 15–24 mm, 25–34 mm, 35–44 mm and ≥45 mm, respectively. In comparison with the smallest tumour sizes (<15 mm), the rates of non-aggressive cancers were not statistically significantly different for tumour sizes 15–24 mm ($p=0.36$), 25–34 mm ($p=0.57$), 35–44 mm ($p=0.38$) and tumour sizes >45 mm ($p=0.30$). The estimated rates of non-aggressive cancers by histology were: adenocarcinoma, 4.5% (95% CI: 1.2% to 7.7%); squamous cell carcinoma, 0.7% (95% CI: 0.0% to 3.1%); large cell, 1.7% (95% CI: 0.0% to

Figure 1 Conditional probability of lung cancer survival

7.9%) and other, 2.2% (95% CI: 0.0% to 5.4%) with $p<0.005$ for all comparisons in reference to adenocarcinoma except for large cell carcinoma ($p=0.28$). For individuals with and without COPD, the estimated rate of non-aggressive cancer was 1.2% (95% CI: 0.0% to 3.3%) and 3.3% (95% CI: 1.3% to 5.3%), $p<0.05$, respectively. When stratifying by age, there was approximately 1.8% non-aggressive cancer (95% CI: 0.0% to 4.1%) in individuals age 65–74, 3.0% (95% CI: 0.4 to 5.6, $p=0.02$) in individuals age 75–84 and 0.9% (95% CI: 0.0% to 4.1%, $p=0.43$) in individuals 85 years of age and older.

DISCUSSION

In our study of untreated, clinically detected stage I NSCLCs, we found overall low (<10%) estimates of non-aggressive cancer regardless of age, sex, tumour histology and size and the presence of COPD, suggesting overdiagnosis of clinically detected NSCLC is relatively uncommon. These results suggest that most early stage lung cancer cases should be considered potentially aggressive and thus treated with a curative intent, a finding that is of particular importance in the management of incidentally found cancers. Biomarkers capable of predicting tumour behaviour are needed to minimise unnecessary treatment of potentially non-aggressive cancers.

Estimates of non-aggressive cancers among clinically detected cancers have yielded a wide range of values, depending on the method of estimation. In a study examining the outcomes of individuals with early stage lung cancer who were not surgically resected, the rate of non-aggressive cancers was estimated to be

Figure 2 Conditional probability of lung cancer survival according to gender

Figure 3 Conditional probability of lung cancer survival according to tumour size

17%, but a majority of patients (80%) did receive some form of treatment (chemotherapy or radiation therapy), and 10% of the cancers were of the small cell subtype.¹⁹ In a separate study of SEER data, the rate of non-aggressive cancers was estimated using the Kaplan-Meier method to control for non-cancer deaths as opposed to using a more valid competing risks framework.²⁰ In a comprehensive review of studies that have examined growth rate, complementary DNA composition and autopsy analysis, along with trial data (primarily of chest radiography studies), the rate of non-aggressive cancers ranged from 11% to 25% but was deemed to be difficult to accurately quantify, although of clinical significance in relation to screening.²¹

The rate of overdiagnosis among screen-detected cancers is likely to be different as screening with CT may unveil small, slowly progressive cancers that are biologically dissimilar. Data from the NLST included 8 years of follow-up, yielding a rate of overdiagnosis, defined as the excess NSCLCs detected by CT divided by all CT screen-detected NSCLCs, of 22%, an estimate that will likely decline as more follow-up is accrued.⁷ Modelling studies that have been extensively used to study the comparative effectiveness of various screening scenarios and have informed recommendations by the United States Preventive Services Task Force (USPSTF) can also estimate the extent of overdiagnosis associated with screening.²² Modelling studies have found an average overdiagnosis rate of 11.9% in the age range recommended by the USPSTF. In light of different recommended ages at which to screen for lung cancer by different organisations, overdiagnosis may serve as useful metric by which to assess the benefits and harms of lung cancer screening, as in their analysis,

Figure 4 Conditional probability of lung cancer survival according to tumour histology

Figure 5 Conditional probability of lung cancer survival according to the presence of COPD

stopping screening at earlier age led to fewer overdiagnosed cases per lung cancer death averted.²³

Our findings must be considered in light of certain strengths and limitations of our study. First, our analysis consists of stage I NSCLCs largely in individuals >65 years of age, diagnosed prior to the advent of widespread lung cancer screening, and thus represent cancers detected clinically. It is unlikely that we can extrapolate our findings to younger individuals or to stage I NSCLCs detected through screening. However, we expect that the smaller cancers (<15 mm) were likely asymptomatic and detected on imaging incidentally and thus similar to cancers diagnosed by screening. Additionally, analyses limited to individuals who underwent a baseline chest CT showed similar rates of overdiagnosis. Second, we were limited by the noted cause of death as reported by the death certificate data, which is subject to inaccuracies. However, studies assessing the validity of death certificate data suggest that the use of cause of death data obtained from death certificates was not significantly different from cause of death determined by a mortality review committee.²⁴ Third, we did not have information on reason for lack of treatment in these individuals (either poor medical fitness for surgery or surgical inoperability), as these individuals may have a different risk of lung cancer death than the group that received treatment and may give a different estimate of the rate of non-aggressive cancers. Additionally, we were limited by a lack of information on smoking history, a variable not captured in SEER-Medicare, and incomplete values of tumour size, due to missing information in SEER. Finally, we were limited by an inability to assess the rate of non-aggressive cancers in minimally

Figure 6 Conditional probability of lung cancer survival according to age

invasive adenocarcinoma and adenocarcinoma in situ, as these were previously classified within the adenocarcinoma subtype. However, our study had several strengths, notably the use of nationally representative data with large numbers of individuals as well as precise estimation and analyses of subgroups. Additionally, we were able to construct our survival curves using long-term follow-up information that allowed for the accurate assessment of curve plateau. Finally, with our use of competing risks methods, we were able to appropriately adjust for deaths from other causes leading to overdiagnosis of estimates with limited bias.

In our population-based assessment of stage I NSCLCs, we found low rates of non-aggressive cancers overall as well as in stratified analyses, after adjusting for competing risks. These results are useful for the management of clinically detected, early stage cancers and suggest that most cases should be considered for curative resection.

Acknowledgements This study used the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare Database. The interpretation and reporting of these data are the sole responsibility of the authors. The authors acknowledge the efforts of the Applied Research Program, National Cancer Institute; the Office of Research, Development and Information, Centers for Medicare and Medicaid Services; Information Management Services (IMS), Inc and SEER Program tumour registries in the creation of the SEER-Medicare Database. The authors would also like to thank Joey Kong, PhD, for his thoughtful comments.

Contributors Study concept and design: MSK, GM, KS and JPW. Acquisition, analysis or interpretation of data: MSK, GM, KS and JPW. Drafting of the manuscript: MSK. Critical revision of the manuscript for important intellectual content: GM, KS and JPW.

Competing interests JPW is a member of the research board of EHE International, has received consulting honorarium from Quintiles, AstraZeneca and Merck and a research grant from Aventis Pharmaceutical and Quorum. KS has received honorarium from Gilead.

Ethics approval Icahn School of Medicine Institutional review board.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement MSK had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

- Welch HG, Black WC. Overdiagnosis in cancer. *J Natl Cancer Inst* 2010;102:605–13.
- Esserman LJ, Thompson IM, Reid B, et al. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. *Lancet Oncol* 2014;15:e234–e242.
- Marcus PM, Prorok PC, Miller AB, et al. Conceptualizing overdiagnosis in cancer screening. *J Natl Cancer Inst* 2015;107:djv014.
- Eddy DM. Screening for lung cancer. *Ann Intern Med* 1989;111:232–7.
- Kubik A, Parkin DM, Khat M, et al. Lack of benefit from semi-annual screening for cancer of the lung: follow-up report of a randomized controlled trial on a population of high-risk males in Czechoslovakia. *Int J Cancer* 1990;45:26–33.
- de Koning HJ, Meza R, Plevritis SK, et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. *Ann Intern Med* 2014;160:311–20.
- Patz EF, Pinsky P, Gatsonis C, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. *JAMA Intern Med* 2014;174:269–74.
- Infante M, Cavuto S, Lutman FR, et al. Long-term follow-up results of the DANTE Trial, a randomized study of lung cancer screening with spiral computed tomography. *Am J Respir Crit Care Med* 2015;191:1166–75.
- Patz EF. Lung cancer screening, overdiagnosis bias, and reevaluation of the Mayo Lung Project. *J Natl Cancer Inst* 2006;98:724–5.
- Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. *Med Care* 2002;40(8 Suppl):IV-3–18.
- Institute NC. Surveillance, epidemiology, and end results: NIH. 2012 http://seer.cancer.gov/about/factsheets/SEER_brochure.pdf (accessed Mar 2012).
- Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. *J Clin Epidemiol* 2000;53:1258–67.
- Klabunde CN, Legler JM, Warren JL, et al. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. *Ann Epidemiol* 2007;17:584–90.
- Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. *Chest* 2009;136:260–71.
- Bach PB, Guadagnoli E, Schrag D, et al. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. *Med Care* 2002;40(8 Suppl):IV-19–25.
- Buell PE. The importance of tumor size in prognosis for resected bronchogenic carcinoma. *J Surg Oncol* 1971;3:539–51.
- Pintilie M. *Competing risks: a practical perspective*. Chichester, England; Hoboken, NJ: John Wiley & Sons, 2006; xiii:224.
- JKaM M. *Survival analysis: techniques for censored and truncated data*. New York, NY: Springer, 1997.
- Sobue T, Suzuki T, Matsuda M, et al. Survival for clinical stage I lung cancer not surgically treated: comparison between screen-detected and symptom-detected cases. *Cancer* 1992;69:685–92.
- Henschke CI, Wisnivesky JP, Yankelevitz DF, et al. Small stage I cancers of the lung: genuineness and curability. *Lung Cancer* 2003;39:327–30.
- Reich JM. A critical appraisal of overdiagnosis: estimates of its magnitude and implications for lung cancer screening. *Thorax* 2008;63:377–83.
- Moyer VA; U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 2014;160:330–338–8.
- Han SS, Ten Haaf K, Hazelton WD, et al. The impact of overdiagnosis on the selection of efficient lung cancer screening strategies. *Int J Cancer* 2017;140:2436–43.
- Doria-Rose VP, Marcus PM. Death certificates provide an adequate source of cause of death information when evaluating lung cancer mortality: an example from the Mayo Lung Project. *Lung Cancer* 2009;63:295–300.